Yes, immune infusion therapies are very much part of myeloma treatment — and the options have grown significantly in recent years. One well-established option is intravenous immunoglobulin (IVIG), which is used to help boost antibody levels and reduce infection risk, especially for those with low antibody counts. Beyond Show Full Answer
Yes, immune infusion therapies are very much part of myeloma treatment — and the options have grown significantly in recent years. One well-established option is intravenous immunoglobulin (IVIG), which is used to help boost antibody levels and reduce infection risk, especially for those with low antibody counts. Beyond IVIG, there are several immunotherapy-based infusion treatments used in myeloma, particularly for relapsed or refractory cases. These include:
- Monoclonal antibodies like daratumumab (Darzalex), elotuzumab (Empliciti), and isatuximab (Sarclisa), given by infusion
- CAR T-cell therapies like idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti)
- Bispecific antibodies like teclistamab (Tecvayli) and elranatamab (Elrexfio), which are newer options
Each of these works by directing the immune system to target and destroy myeloma cells.
It's worth noting that side effects can vary — common ones include fatigue, fever, nausea, and increased infection risk. More serious but rare effects like cytokine release syndrome are possible with some therapies.
Always worth a conversation with your oncologist about which option, if any, fits your current treatment stage.
July 25
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
